Clinical Research

Basics of Clinical Research & ICH-GCP: Phases, Ethics & Harmonisation


Every new medicine reaches the clinic the same way — through a disciplined sequence of preclinical testing and then clinical trials in phases, all governed by Good Clinical Practice (GCP). This is the foundation topic for the Clinical Research paper: get the phases, the ethics and the ICH framework clear and the rest of the syllabus falls into place.

From molecule to market — the phases of a clinical trial Preclinical (in-vitro & animal) precedes Phase I increasing number of subjects → Phase 0 Healthy, ~10Microdose(≤100 µg)Exploratoryhuman PK/PD;no efficacy Phase I Healthy, 20–80First-in-humanSafety,tolerability,PK/PD, dose-ranging, MTD Phase II Patients, 100–300Proof-of-conceptefficacy, dose-finding (IIa/IIb),short-term safety Phase III Patients, 300–3000+Confirmatoryefficacy vscontrol;multicentric RCT→ approval Phase IV Real-world, largePost-marketingsurveillance:rare/long-termADRs, interactions,new indications
Phase 0–IV: subjects increase and the question shifts from safety (I) to efficacy (II–III) to real-world safety (IV).

What is clinical research?

Clinical research is the systematic study of the safety and efficacy of drugs, devices, diagnostics and treatment regimens in human subjects. The ICH-GCP definition of a clinical trial is any investigation in human subjects intended to discover or verify the clinical, pharmacological or pharmacodynamic effects of an investigational product, and/or identify adverse reactions, and/or study its ADME — to ascertain safety and/or efficacy. (“Clinical trial” and “clinical study” are synonymous.)

Types of clinical research

  • Observational — the investigator does not allocate the intervention: cohort, case-control, cross-sectional, and case series/report studies.
  • Interventional / experimental — the investigator assigns the intervention: randomised controlled trials (RCTs) and non-randomised trials.
  • By objective — therapeutic, diagnostic, preventive (vaccines), screening, and supportive-care / quality-of-life research.
  • Therapeutic vs non-therapeutic — whether the subject may directly benefit from participating.

Phases of clinical trials

PhaseSubjects (n)Primary purpose
Phase 0Healthy, ~10 (microdose)Exploratory human PK/PD with sub-therapeutic microdoses (≤100 µg); no efficacy/safety claim.
Phase IHealthy, 20–80 (patients for cytotoxics)First-in-human safety, tolerability, PK/PD, dose-ranging and maximum tolerated dose (MTD).
Phase IIPatients, 100–300Proof-of-concept efficacy, dose-finding (IIa dose, IIb efficacy) and short-term safety.
Phase IIIPatients, 300–3000+Confirmatory efficacy vs placebo/standard; basis for marketing approval. Multicentric RCTs.
Phase IVReal-world, large populationPost-marketing surveillance — rare/long-term ADRs, interactions, new indications.

India’s NDCT 2019 / Schedule Y use equivalent terms: Human Pharmacology (I), Therapeutic Exploratory (II), Therapeutic Confirmatory (III) and Post-marketing (IV).

Core study-design concepts

  • Randomisation — random allocation removes selection bias and balances confounders across groups.
  • Blinding (masking) — single / double / triple blind; reduces performance and assessment bias.
  • Control — placebo or active comparator; parallel vs crossover designs.
  • Hypothesis — superiority, non-inferiority or equivalence.
  • Endpoints — primary, secondary and surrogate, all defined a priori.
  • Analysis sets — intention-to-treat (ITT) vs per-protocol; Type I (α) and Type II (β) errors and statistical power.

Ethical foundations

Modern research ethics grew out of past abuses (Nazi experiments; the Tuskegee syphilis study), through successive safeguards:

Milestone (year)Contribution
Nuremberg Code (1947)First code on human experimentation; voluntary consent is essential (10 points).
Declaration of Helsinki (1964)WMA ethical principles for medical research; revised through 2013 (Fortaleza) and 2024.
Belmont Report (1979)Three principles — respect for persons, beneficence, justice.
CIOMS / ICMR / ICH-GCPInternational and national operational guidelines for ethical trial conduct.

ICH and GCP

The ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; until 2015 “Conference”) was founded in 1990 and became a Swiss legal entity in 2015. It harmonises regulatory requirements across the founding regions — EU, USA (FDA) and Japan (MHLW) — to avoid duplication, speed patient access and reduce unnecessary animal/human testing. Its guidelines are grouped as:

  • Q — Quality (stability, impurities, GMP, quality risk management).
  • S — Safety (nonclinical toxicology, safety pharmacology, carcinogenicity).
  • E — Efficacy (clinical studies). Good Clinical Practice is ICH E6 — the international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve human subjects.
  • M — Multidisciplinary (e.g. the MedDRA dictionary, CTD format).
Exam tip: Phase I = healthy volunteers, safety/MTD; Phase II = efficacy & dose-finding; Phase III = confirmatory RCT for approval; Phase IV = post-marketing. GCP = ICH E6. Nuremberg → voluntary consent; Helsinki → WMA principles; Belmont → respect, beneficence, justice. Know the India/NDCT equivalent phase names.

Clinical research is simply ethics plus method, applied in sequence: prove safety, then efficacy, then watch the real world — all under GCP. Anchor the phases and the ethical milestones, and every later topic (consent, protocol, monitoring, safety reporting) is just detail hung on this frame.

Share

Clinical Research
← All articles